Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Rating of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has earned an average recommendation of “Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and four have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $11.50.

Several research firms have recently issued reports on CATX. BTIG Research initiated coverage on Perspective Therapeutics in a report on Friday, October 10th. They issued a “buy” rating and a $14.00 target price for the company. B. Riley reduced their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd. UBS Group reissued a “buy” rating and issued a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. Finally, Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, November 11th.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX traded down $0.13 during trading on Wednesday, hitting $2.72. The stock had a trading volume of 323,768 shares, compared to its average volume of 1,105,402. The firm has a fifty day moving average of $2.79 and a two-hundred day moving average of $3.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $5.39.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%. As a group, sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Perspective Therapeutics in the third quarter worth $46,000. Ground Swell Capital LLC bought a new stake in shares of Perspective Therapeutics in the second quarter valued at $56,000. Los Angeles Capital Management LLC purchased a new position in shares of Perspective Therapeutics during the 2nd quarter valued at $61,000. Finally, Mercer Global Advisors Inc. ADV lifted its position in shares of Perspective Therapeutics by 81.8% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock valued at $100,000 after buying an additional 13,168 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.